Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients - Quiz - MDSpire

Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients

  • By

  • Christian Nelles

  • Moritz Gräf

  • Pascale Bernard

  • Thorsten Persigehl

  • Nils Große Hokamp

  • David Zopfs

  • David Maintz

  • Nicole Kreuzberg

  • Jürgen Wolf

  • Paul J. Bröckelmann

  • Simon Lennartz

  • September 18, 2024

  • 0 min

Share

Original Source(s)

Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients

  • by Christian Nelles, Moritz Gräf, Pascale Bernard, Thorsten Persigehl, Nils Große Hokamp, David Zopfs, David Maintz, Nicole Kreuzberg, Jürgen Wolf, Paul J. Bröckelmann, Simon Lennartz

  • September 18, 2024

Related Content

Comprehensive Evaluation of Biological Age Post-Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer Patients

Case Report: Long-term survival in advanced PD-L1-high squamous cell lung cancer following severe immune-related cardiotoxicity

Development of a CT-based comprehensive model with deep learning for differentiating pathological types of pulmonary ground-glass nodules